Floatz logo

TACROLIMUS

Mast Cell Leukemia

Fred Hutchinson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Mast Cell Leukemia cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Stanford University
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Avapritinib
Blueprint Medicines Corporation
Phase 2BB
Solu-Cortef
Stanford University
Phase 2B
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B

View all 24 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →